Opaleye Management’s Cidara Therapeutics CDTX Stock Holding History

Opaleye Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,668	Closed	-$148K	–	49
2021 Q2	$148K	Buy	+3,668	New	+$155K	0.02%	47
2020 Q4	–	Sell	-48,533	Closed	-$2.77M	–	60
2020 Q3	$2.77M	Hold	48,533	–	–	0.54%	41
2020 Q2	$3.58M	Buy	48,533 +3,230	+7%	+$209K	0.72%	36
2020 Q1	$2.25M	Buy	+45,303	New	+$2.71M	0.6%	34
2019 Q2	–	Sell	-50,000	Closed	-$2.65M	–	47
2019 Q1	$2.65M	Sell	50,000 -10,000	-17%	-$548K	0.73%	42
2018 Q4	$2.82M	Hold	60,000	–	–	1.05%	30
2018 Q3	$5.28M	Hold	60,000	–	–	1.34%	26
2018 Q2	$6.24M	Buy	+60,000	New	+$5.66M	1.62%	23
2017 Q2	–	Sell	-6,125	Closed	-$955K	–	43
2017 Q1	$955K	Buy	+6,125	New	+$1.08M	0.48%	37
2016 Q3	–	Sell	-2,150	Closed	-$443K	–	46
2016 Q2	$443K	Buy	+2,150	New	+$520K	0.3%	47

Other funds holding CDTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Opaleye Management's CDTX Position: Q3 2021 in Review

Opaleye Management sold out of Cidara Therapeutics (CDTX) in Q3 2021, closing a stake of 3,668 shares — an estimated $148K sold.

Opaleye Management first reported a position in CDTX in Q2 2016 and held it in 10 quarters. The position peaked at $6.24M in Q2 2018. 50 funds tracked by Wall St. Rank hold CDTX as of Q3 2021.

Opaleye Management reported no remaining Cidara Therapeutics position as of Q3 2021 after selling out during the quarter.
Opaleye Management sold 3,668 Cidara Therapeutics shares in Q3 2021, an estimated $148K.
Opaleye Management first reported a position in Cidara Therapeutics in Q2 2016 and held it in 10 quarters.
Opaleye Management's Cidara Therapeutics position peaked at $6.24M in Q2 2018.
50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2021.

Based on Opaleye Management's 13F filing for Q3 2021, filed 16 Nov 2021.